PTC THERAPEUTICS, INC.

PTCT 10-Q · Q1 2026
API behind this page

PTCT Q1 2026 request

Playground key active
Request URL /api/financials?ticker=PTCT&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 272,551 1,176,096 -76.8%
Show Product Lines breakouts
All other products 10,974 10,824 +1.4%
All other products · Non Us 10,974 10,824 +1.4%
Collaboration and license revenue 143 986,231 -100.0%
Collaboration and license revenue · Novartis 0.1 989.8 -100.0%
Emflaza 21,478 47,789 -55.1%
Emflaza · US 21,478 47,789 -55.1%
Product 225,573 153,426 +47.0%
Product · Non Us 89,057 105,637 -15.7%
Product · US 136,516 47,789 +185.7%
Royalty 46,835 36,439 +28.5%
Royalty · Collaborative Arrangement 46.8 36.4 +28.6%
Sephience 124,551 — —
Sephience · Non Us 12,511 — —
Sephience · US 112,040 — —
Translarna 58,976 86,154 -31.5%
Translarna · Non Us 58,976 86,154 -31.5%
Upstaza/Kebilidi 9,594 8,659 +10.8%
Upstaza/Kebilidi · Non Us 6,596 8,659 -23.8%
Upstaza/Kebilidi · US 2,998 — —
Show Business Segments breakouts
Life Science · Operating Segments 272,551 1,176,096 -76.8%
Show Geography breakouts
All other countries 44,596 57,618 -22.6%
BR 41,212 9,505 +333.6%
RU 3,249 38,514 -91.6%
US 136,516 47,789 +185.7%
Cost Of Goods And Service Excluding Amortization Of Intangible Assets 28,028 12,862 +117.9%
Amortization Of Intangible Assets 11,581 3,798 +204.9%
Show Business Segments breakouts
Life Science · Operating Segments 11,581 3,798 +204.9%
Show Fair Value By Asset Class breakouts
Finite Lived Intangible Assets 11,581 3.8 +304663.2%
Finite Lived Intangible Assets · Kebilidi 486 — —
Finite Lived Intangible Assets · Sephience 5,085 — —
Finite Lived Intangible Assets · Tegsedi 1,134 — —
Finite Lived Intangible Assets · Upstaza 3,975 — —
Finite Lived Intangible Assets · Waylivra 901 — —
Research & Development 100,873 108,973 -7.4%
Selling, General & Administrative 86,183 80,961 +6.5%
Gain Loss On Disposition And Impairment Of Tangible Assets 927 77 +1103.9%
Operating Expenses 227,592 205,871 +10.6%
Operating Income 44,959 970,225 -95.4%
Interest Income Expense Nonoperating Net -49,030 -34,092 -43.8%
Other Non-Operating Income (Expense) 1,609 -6,305 +125.5%
Income Before Taxes -2,462 929,828 -100.3%
Income Tax Expense (Benefit) -347 -63,266 +99.5%
Show Business Segments breakouts
Life Science · Operating Segments -347 -63,266 +99.5%
Net Income -2,809 866,562 -100.3%
Show Business Segments breakouts
Life Science · Operating Segments -2,809 866,562 -100.3%
Show Equity Components breakouts
Retained Earnings -2,809 866,562 -100.3%
Wtd Avg Shares (Basic) 82,521,023 78,115,836 +5.6%
Wtd Avg Shares (Diluted) 82,521,023 86,385,922 -4.5%
EPS (Basic) -0.03 11.09 -100.3%
EPS (Diluted) -0.03 10.04 -100.3%
Interest Expense (Q) — — —
Show Business Segments breakouts
Life Science · Operating Segments 67,015 51,337 +30.5%
Interest Income (Q) — — —
Show Business Segments breakouts
Life Science · Operating Segments -17,985 -17,245 -4.3%
Comprehensive Income -4,844 878,499 -100.6%
Other Comprehensive Income -2,035 11,937 -117.0%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -2,035 11,937 -117.0%
Net Income Loss Available To Common Stockholders Basic -2,809 866,562 -100.3%
Labor And Related Expense (Q) — — —
Show Business Segments breakouts
Life Science · Operating Segments 76,121 67,699 +12.4%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 833,986 1,480,231 -43.7%
Marketable Securities (Current) 1,058,477 546,950 +93.5%
Receivables Net Current 219,919 210,495 +4.5%
Inventory 75,567 — —
Prepaid Expenses & Other Current Assets 66,054 57,055 +15.8%
Total Current Assets 2,254,003 2,316,406 -2.7%
Non-Current Assets
Property, Plant & Equipment 52,739 59,459 -11.3%
Goodwill 82,341 82,341 0.0%
Operating Lease Right-of-Use Assets 76,692 57,317 +33.8%
Deposits And Other Assets Noncurrent 22,645 21,416 +5.7%
Total Assets 2,869,104 2,655,387 +8.0%
Intangible Assets 380,684 118,448 +221.4%
Show Fair Value By Asset Class breakouts
Finite Lived Intangible Assets 380,684 118,448 +221.4%
Other Assets
Intangible Assets Net Excluding Goodwill 380,684 118,448 +221.4%
Current Liabilities
Accounts Payable And Accrued Liabilities Current 313,050 317,807 -1.5%
Current Portion of Long-Term Debt 286,937 — —
Deferred Revenue (Current) 498 — —
Operating Lease Liability Current 12,078 11,464 +5.4%
Finance Lease Liability Current 6,000 — —
Liability Sale Of Future Royalties Current 305,041 248,240 +22.9%
Total Current Liabilities 923,604 595,391 +55.1%
Accounts Payable 25,484 15,150 +68.2%
Non-Current Liabilities
Operating Lease Liabilities 90,072 73,559 +22.4%
Liability Sale Of Future Royalties Noncurrent 2,022,189 1,850,223 +9.3%
Other Non-Current Liabilities 13,704 22,429 -38.9%
Total Liabilities 3,049,569 2,841,147 +7.3%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
2026 Convertible Notes · Convertible Debt 286,937 — —
Stockholders' Equity
Common Stock 81 78 +3.8%
Additional Paid-In Capital 2,778,026 — —
Accumulated Other Comprehensive Income 8,466 -13,949 +160.7%
Retained Earnings -2,967,038 -2,780,311 -6.7%
Total Stockholders' Equity -180,465 -185,760 +2.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 8,466 -13,949 +160.7%
Additional Paid In Capital 2,778,026 2,608,422 +6.5%
Common Stock 81 78 +3.8%
Retained Earnings -2,967,038 -2,780,311 -6.7%
Total Liabilities & Equity 2,869,104 2,655,387 +8.0%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation & Amortization 15,413 7,221 +113.4%
Operating Lease Right Of Use Asset Amortization Expense 1,761 1,790 -1.6%
Noncash Royalty Revenue Sale Of Future Royalties -46,835 -32,974 -42.0%
Noncash Interest Expense Liability Related To Sale Of Future Royalties 65,699 49,661 +32.3%
Equity Securities Fv Ni Unrealized Gain Loss -1,214 -774 -56.8%
Show Investment Type breakouts
Equity Securities -1,214 -774 -56.8%
Deferred Income Taxes -10 2 -600.0%
Accretion Amortization Of Discounts And Premiums Investments -4,114 -2,313 -77.9%
Amortization of Financing Costs 305 299 +2.0%
Show Debt Instrument breakouts
2026 Convertible Notes · Convertible Debt 305 299 +2.0%
Stock-Based Compensation 23,421 18,060 +29.7%
Foreign Currency Transaction Gain Loss Unrealized -887 2,251 -139.4%
Change in Inventory 2,643 2,191 +20.6%
Change in Prepaid & Other Assets 1,180 -16,429 +107.2%
Increase Decrease In Receivables -40,390 -47,792 +15.5%
Increase Decrease In Deposit Other Assets -1,588 -611 -159.9%
Increase Decrease In Accounts Payable And Accrued Liabilities -68,713 18,502 -471.4%
Increase Decrease In Other Operating Liabilities -2,309 -458 -404.1%
Change in Deferred Revenue -1,522 7,200 -121.1%
Net Cash from Operations -59,042 870,103 -106.8%
Investing Activities
Capital Expenditures -1,197 -1,724 +30.6%
Purchases of Investments -454,670 -322,335 -41.1%
Payments To Acquire Marketable Securities -23,957 -5,209 -359.9%
Show Investment Type breakouts
Equity Securities -23,957 -5,209 -359.9%
Proceeds From Sale Of Available For Sale Securities Debt 376,359 136,750 +175.2%
Proceeds From Sale And Maturity Of Marketable Securities 9,885 8,896 +11.1%
Show Investment Type breakouts
Equity Securities 9,885 8,896 +11.1%
Payments To Acquire Intangible Assets -156 -808 +80.7%
Net Cash from Investing -93,736 -184,360 +49.2%
Financing Activities
Proceeds From Stock Options Exercised 6,403 15,751 -59.3%
Net Cash from Financing 6,403 9,410 -32.0%
Supplemental
Interest Paid 2,156 2,156 0.0%
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent -1,517 -88 -1623.9%
Decrease In Operating Lease Right Of Use Assets Related To Lease Modifications And Terminations 1,466 — —
Decrease In Operating Lease Liability Related To Lease Modifications And Terminations 1,547 — —
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 5,292 2,185 +142.2%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -1,524 5,393 -128.3%
Net Change in Cash -147,899 700,546 -121.1%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 850,435 1,495,862 -43.1%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key